Tirzepatide is a single 39-amino-acid peptide that activates both the GIP and GLP-1 receptors — and what the trials measured is remarkable.

The short version

Tirzepatide is a synthetic peptide — a short chain of 39 amino acids — that was designed in a laboratory to mimic two natural gut hormones at once. Those hormones, called GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), are normally released after a meal to signal the pancreas to make insulin and to tell the brain you are full. Tirzepatide activates both of their receptors simultaneously with a single molecule — an approach never tried in an approved drug before it.

The FDA approved tirzepatide for type 2 diabetes in May 2022, for chronic weight management in November 2023, and later for moderate-to-severe obstructive sleep apnea in adults with obesity. In major clinical trials it reduced body weight by up to 20.9% over 72 weeks and cut blood sugar levels more than any previously approved agent in head-to-head comparisons. It is given as a once-weekly subcutaneous (under-the-skin) injection, starting at a low dose and stepping up over several months.

This site is an editorial reading of the published research — the mechanism papers, the phase 3 trials, the safety analyses. What Tirzepatide effects look like in practice — including the downsides — is on the effects page.

One peptide, two receptors: what the mechanism research established

Tirzepatide (also known by its development code LY3298176) was disclosed in a 2018 paper by Coskun et al. as a fatty-acid-modified 39-amino-acid peptide engineered from the native GIP backbone ^[1]. The fatty-diacid arm — a C20 eicosanedioic acid moiety attached via a glutamic acid linker and two aminoethoxyethoxy-acetic acid units to a lysine side chain — confers strong albumin binding, stretching the elimination half-life to approximately five days and making once-weekly dosing workable ^[1].

In the 2018 discovery study, tirzepatide activated both GIP receptor and GLP-1 receptor signalling in vitro and produced greater reductions in body weight and food intake in mice than a selective GLP-1 receptor agonist — an early proof that dual-receptor engagement could outperform single-receptor agonism ^[1]. A Phase 1 programme in 142 subjects confirmed pharmacokinetics consistent with once-weekly administration and showed reduced fasting glucose and body weight versus placebo ^[1].

The receptor pharmacology was characterised in depth by Willard et al. (2020), who found tirzepatide is an imbalanced dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor, and it shows biased GLP-1 receptor signalling that favours cyclic AMP (cAMP — a second messenger that triggers insulin release inside the cell) generation over beta-arrestin recruitment (the pathway that causes the receptor to be pulled off the cell surface and silenced) ^[2]. The result is sustained receptor activity and enhanced insulin secretion compared with a non-biased agonist ^[2].

Novikoff et al. (2021) added a spatiotemporal dimension: using live-cell microscopy, they showed tirzepatide produced preserved maximal cAMP output despite only partial activation of the Gαs protein (the G-protein that generates cAMP), paired with diminished receptor internalisation at both GLP-1R and GIPR ^[4]. Less receptor internalisation means the receptors stay on the cell surface longer, sustaining the signal. The tirzepatide mechanism of action is explored in depth on the dedicated page.

The SURPASS and SURMOUNT programmes: what the phase 3 trials measured

SURPASS-2, a 40-week phase 3 open-label trial in 1,879 adults with type 2 diabetes, was the first direct head-to-head comparison against semaglutide 1 mg ^[3]. Tirzepatide at 5, 10, and 15 mg once weekly reduced HbA1c (glycated haemoglobin — the standard three-month blood-sugar marker) by 2.01, 2.24, and 2.30 percentage points respectively, versus 1.86 percentage points with semaglutide — superior at all three doses ^[3]. Body weight reductions were also greater with tirzepatide: treatment differences of -1.9, -3.6, and -5.5 kg at the three doses ^[3].

For obesity and weight management, SURMOUNT-1 is the pivotal dataset. In a 72-week double-blind placebo-controlled trial of 2,539 adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) and without diabetes, tirzepatide at 5, 10, and 15 mg once weekly produced mean weight changes of -15.0%, -19.5%, and -20.9% respectively versus -3.1% with placebo ^[5]. The most common adverse events were gastrointestinal and mostly mild to moderate, occurring primarily during dose escalation ^[5].

The most recent head-to-head data comes from SURMOUNT-5, a 2025 NEJM paper by Aronne et al.: in 751 adults with obesity but without type 2 diabetes, randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks, weight change was -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001) ^[6]. Greater reductions in waist circumference and higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss were all statistically significant ^[6].

See Tirzepatide research for the full trial record.

Tirzepatide peptide: what the structure does that prior drugs could not

The tirzepatide peptide is structurally unlike any previously marketed incretin therapy. Native GIP is a 42-amino-acid peptide; native GLP-1 is 30 amino acids. Tirzepatide is a 39-amino-acid synthetic peptide built on the GIP backbone — not a fusion of two separate molecules, but a single engineered sequence that activates both receptors ^[1]. The C20 fatty-diacid acylation is what confers the five-day half-life that makes once-weekly injection practical ^[1].

The pharmacological consequence of hitting both receptors simultaneously is not simply additive. The GIPR arm of tirzepatide's action involves a state-dependent role in adipose tissue: Regmi et al. (2024) showed that long-acting GIPR agonism cooperates with insulin to augment glucose uptake and lipid clearance in human adipocytes in the fed state, while enhancing lipolysis when insulin is low in the fasted state ^[8]. This nutrient-buffering role in fat tissue — distinct from GLP-1's primary pancreatic and brain actions — appears to contribute to reduced circulating triglycerides and a more favourable fat-loss profile ^[8].

A 2025 mechanistic review by Samms et al. framed the GIPR arm as complementary at the level of the CNS: GIPR agonism in the brain attenuates nausea and suppresses appetite synergistically with GLP-1R, while adipose GIPR activity protects against ectopic fat deposition ^[9]. The tirzepatide peptide is, in this view, a two-key mechanism designed to exploit the full incretin axis rather than a single pathway.

Tirzepatide results: the trial record across approved indications

Beyond glycaemia and weight, the clinical programme has extended into several additional indications. SURMOUNT-OSA, a 52-week trial in adults with obesity and moderate-to-severe obstructive sleep apnea (OSA), found tirzepatide reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep) by 25.3 events/hour in PAP-naive participants and 29.3 events/hour in PAP users, versus roughly 5 events/hour with placebo ^[13]. This led to FDA approval for OSA in adults with obesity — the first new OSA pharmacotherapy in decades.

SUMMIT, a 2025 NEJM paper by Packer et al., examined heart failure with preserved ejection fraction (HFpEF — a form of heart failure in which the pumping fraction of the heart remains normal, more common in obesity) in adults with obesity. Tirzepatide reduced heart-failure events and improved functional status versus placebo ^[14].

Early response predicts long-term outcomes but non-responders still benefit: a 2025 post-hoc pooled SURPASS analysis (n=3,676 for fasting serum glucose; n=4,121 for weight) found that early glycaemic response (≥20% fasting glucose reduction at week 4) or early weight response (≥5% at week 8) predicted better long-term HbA1c and metabolic outcomes — but non-early responders still achieved clinically meaningful reductions at all doses ^[10].

For Tirzepatide references, see the full citation list.